Impella recover 100 microaxial left ventricular assist device: The Niguarda experience

A. Garatti, T. Colombo, C. Russo, M. Lanfranconi, G. Bruschi, F. Milazzo, E. Catena, E. Vitali

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background The Impella Recover 100 (IR100) is an intravascular microaxial blood pump used to support blood circulation for a maximum of 7 days in cases of reduced left ventricular function, for example in postcardiotomy low output syndrome or in cardiogenic shock after acute myocardial infarction. Materials and methods We supported five patients with the IR100. The mean age, cardiac index (CI), and ejection fraction (EF) of our population were 42 years, 1.83 L/min/m2, and 20%, respectively. Two patients (group A) with ischemic dilated cardiomyopathy were bridged to heart transplant. Two patients (group B) with fulminan myocarditis and septic shock were bridged to recovery. One patient, with severe valvular cardiomyopathy who underwent aortic valve replacement and mitral valve annuloplasty, was supported to weaning from ECC. Results Mean support time was 9.8 ± 2.3 days. Only one acute myocarditis patient died from a severe vasoplegic syndrome despite maximal inotropic and vasoactive support. Both group A patients were succesfully transplanted. Among group B, the second patient resolved the septic status and was slowly weaned from the device and discharged home with moderate improvement of LV function (EF = 40%). Patient C was weaned from the IR100 and electively placed on the heart transplant recipient list. Conclusions IR100 is a device that in our experience can be utilized for various indications for short-term support. In compromised patients where a traditional LVAD is contraindicated, the IR100 showed good results, for it is minimally invasive and does not need ECC or systemic anticoagulation.

Original languageEnglish
Pages (from-to)623-626
Number of pages4
JournalTransplantation Proceedings
Volume36
Issue number3
DOIs
Publication statusPublished - Apr 2004

Fingerprint

Heart-Assist Devices
Myocarditis
Vasoplegia
Mitral Valve Annuloplasty
Equipment and Supplies
Cardiogenic Shock
Blood Circulation
Dilated Cardiomyopathy
Septic Shock
Weaning
Cardiomyopathies
Aortic Valve
Left Ventricular Function
Myocardial Infarction
Transplants

ASJC Scopus subject areas

  • Surgery
  • Transplantation

Cite this

Impella recover 100 microaxial left ventricular assist device : The Niguarda experience. / Garatti, A.; Colombo, T.; Russo, C.; Lanfranconi, M.; Bruschi, G.; Milazzo, F.; Catena, E.; Vitali, E.

In: Transplantation Proceedings, Vol. 36, No. 3, 04.2004, p. 623-626.

Research output: Contribution to journalArticle

Garatti, A, Colombo, T, Russo, C, Lanfranconi, M, Bruschi, G, Milazzo, F, Catena, E & Vitali, E 2004, 'Impella recover 100 microaxial left ventricular assist device: The Niguarda experience', Transplantation Proceedings, vol. 36, no. 3, pp. 623-626. https://doi.org/10.1016/j.transproceed.2004.02.051
Garatti, A. ; Colombo, T. ; Russo, C. ; Lanfranconi, M. ; Bruschi, G. ; Milazzo, F. ; Catena, E. ; Vitali, E. / Impella recover 100 microaxial left ventricular assist device : The Niguarda experience. In: Transplantation Proceedings. 2004 ; Vol. 36, No. 3. pp. 623-626.
@article{8c1eb5301bbc459f886fff0851b4c031,
title = "Impella recover 100 microaxial left ventricular assist device: The Niguarda experience",
abstract = "Background The Impella Recover 100 (IR100) is an intravascular microaxial blood pump used to support blood circulation for a maximum of 7 days in cases of reduced left ventricular function, for example in postcardiotomy low output syndrome or in cardiogenic shock after acute myocardial infarction. Materials and methods We supported five patients with the IR100. The mean age, cardiac index (CI), and ejection fraction (EF) of our population were 42 years, 1.83 L/min/m2, and 20{\%}, respectively. Two patients (group A) with ischemic dilated cardiomyopathy were bridged to heart transplant. Two patients (group B) with fulminan myocarditis and septic shock were bridged to recovery. One patient, with severe valvular cardiomyopathy who underwent aortic valve replacement and mitral valve annuloplasty, was supported to weaning from ECC. Results Mean support time was 9.8 ± 2.3 days. Only one acute myocarditis patient died from a severe vasoplegic syndrome despite maximal inotropic and vasoactive support. Both group A patients were succesfully transplanted. Among group B, the second patient resolved the septic status and was slowly weaned from the device and discharged home with moderate improvement of LV function (EF = 40{\%}). Patient C was weaned from the IR100 and electively placed on the heart transplant recipient list. Conclusions IR100 is a device that in our experience can be utilized for various indications for short-term support. In compromised patients where a traditional LVAD is contraindicated, the IR100 showed good results, for it is minimally invasive and does not need ECC or systemic anticoagulation.",
author = "A. Garatti and T. Colombo and C. Russo and M. Lanfranconi and G. Bruschi and F. Milazzo and E. Catena and E. Vitali",
year = "2004",
month = "4",
doi = "10.1016/j.transproceed.2004.02.051",
language = "English",
volume = "36",
pages = "623--626",
journal = "Transplantation Proceedings",
issn = "0041-1345",
publisher = "Elsevier USA",
number = "3",

}

TY - JOUR

T1 - Impella recover 100 microaxial left ventricular assist device

T2 - The Niguarda experience

AU - Garatti, A.

AU - Colombo, T.

AU - Russo, C.

AU - Lanfranconi, M.

AU - Bruschi, G.

AU - Milazzo, F.

AU - Catena, E.

AU - Vitali, E.

PY - 2004/4

Y1 - 2004/4

N2 - Background The Impella Recover 100 (IR100) is an intravascular microaxial blood pump used to support blood circulation for a maximum of 7 days in cases of reduced left ventricular function, for example in postcardiotomy low output syndrome or in cardiogenic shock after acute myocardial infarction. Materials and methods We supported five patients with the IR100. The mean age, cardiac index (CI), and ejection fraction (EF) of our population were 42 years, 1.83 L/min/m2, and 20%, respectively. Two patients (group A) with ischemic dilated cardiomyopathy were bridged to heart transplant. Two patients (group B) with fulminan myocarditis and septic shock were bridged to recovery. One patient, with severe valvular cardiomyopathy who underwent aortic valve replacement and mitral valve annuloplasty, was supported to weaning from ECC. Results Mean support time was 9.8 ± 2.3 days. Only one acute myocarditis patient died from a severe vasoplegic syndrome despite maximal inotropic and vasoactive support. Both group A patients were succesfully transplanted. Among group B, the second patient resolved the septic status and was slowly weaned from the device and discharged home with moderate improvement of LV function (EF = 40%). Patient C was weaned from the IR100 and electively placed on the heart transplant recipient list. Conclusions IR100 is a device that in our experience can be utilized for various indications for short-term support. In compromised patients where a traditional LVAD is contraindicated, the IR100 showed good results, for it is minimally invasive and does not need ECC or systemic anticoagulation.

AB - Background The Impella Recover 100 (IR100) is an intravascular microaxial blood pump used to support blood circulation for a maximum of 7 days in cases of reduced left ventricular function, for example in postcardiotomy low output syndrome or in cardiogenic shock after acute myocardial infarction. Materials and methods We supported five patients with the IR100. The mean age, cardiac index (CI), and ejection fraction (EF) of our population were 42 years, 1.83 L/min/m2, and 20%, respectively. Two patients (group A) with ischemic dilated cardiomyopathy were bridged to heart transplant. Two patients (group B) with fulminan myocarditis and septic shock were bridged to recovery. One patient, with severe valvular cardiomyopathy who underwent aortic valve replacement and mitral valve annuloplasty, was supported to weaning from ECC. Results Mean support time was 9.8 ± 2.3 days. Only one acute myocarditis patient died from a severe vasoplegic syndrome despite maximal inotropic and vasoactive support. Both group A patients were succesfully transplanted. Among group B, the second patient resolved the septic status and was slowly weaned from the device and discharged home with moderate improvement of LV function (EF = 40%). Patient C was weaned from the IR100 and electively placed on the heart transplant recipient list. Conclusions IR100 is a device that in our experience can be utilized for various indications for short-term support. In compromised patients where a traditional LVAD is contraindicated, the IR100 showed good results, for it is minimally invasive and does not need ECC or systemic anticoagulation.

UR - http://www.scopus.com/inward/record.url?scp=2042544807&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2042544807&partnerID=8YFLogxK

U2 - 10.1016/j.transproceed.2004.02.051

DO - 10.1016/j.transproceed.2004.02.051

M3 - Article

C2 - 15110614

AN - SCOPUS:2042544807

VL - 36

SP - 623

EP - 626

JO - Transplantation Proceedings

JF - Transplantation Proceedings

SN - 0041-1345

IS - 3

ER -